Research programme: multivalent infectious diesease DNA vaccines - Imunon
Latest Information Update: 28 Aug 2023
At a glance
- Originator Imunon
- Class Bacterial vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Bacterial infections; Viral infections
Most Recent Events
- 24 Aug 2023 Imunon enters into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases to conduct preclinical studies of PlaCCine DNA constructs against Lassa virus infections
- 20 Jan 2023 QC feedbacks incorporated; confirmed with lead SME based on (https://imunon.com/science/)- retain IM dev line for now, and company might evaluate other ROAs such as intranasal and intradermal in future
- 09 Jan 2023 Celsion files for a provisional patent for a novel DNA-based vaccine, using the PLACCINE DNA vaccine technology platform